Insight journal - Deals and alliances

Current Agreements Deals Update: September 2011

Posted on 07 September 2011

Tags:

Welcome to the September 2011 edition of Current Agreements Deals Update.

This month we are providing you with an overview of deal making activity in the life sciences, covering partnering and M&A in August 2011.

Deal of the month

Development and commercialization agreement for Checkpoint kinase 1 (ChK-1) program
Array Biopharma, Genentech - August 8, 2011  

Array BioPharma has announced an oncology agreement with Genentech for the development of each company's small-molecule Checkpoint kinase 1 (ChK-1) program more

Breaking news...

Collaborative R&D agreement for therapeutic for an undisclosed orphan disease
Mitsubishi Tanabe, Synageva - September 1, 2011

For more breaking deals as they are announced, visit: http://www.currentagreements.com

What's new...

New flexible subscription options now available

Current Agreements is now available on a number of flexible subscription options - fees from $1,000 for a single user.

For further details of What's new at Current Agreements, visit here.

Month In Review

Welcome to the September 2011 edition of Current Agreements Deals Update.

This month we are providing you with an overview of deal making activity in the life sciences, covering partnering and M&A in August 2011.

As we move into the fall, partnering activity appears to continue at a good pace. A total of 257 partnering deals were announced during the month, with the top deal by value being the development and commercialization agreement for Checkpoint kinase 1 (ChK-1) program. The deal had a headline value of USD410 million. Further details can be viewed here.

M&A also saw significant activity with 37 deals announced, with the leading deal being the acquisition of Liberty Dialysis by Fresenius Medical Care for USD1.7 billion. Full details here.

With the emerging role of personalized medicine in recent dealmaking we have published a series of reports:

To see the leading deals of 2011 so far, view the set of Scorecards for 2011: Top partnering deals 2011 | Top M&A deals 2011 - check them out.

We have also recenly updated our highly popular Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report - further details here.

Finally, we have recently introduced new, flexible subscription options. You can now subscribe to Current Agreements for as little at USD1,000. View full subscription options.

We welcome your comments and feedback on this newsletter. We also welcome contact from any company that has a deal not already announced by press release, allowing us to add non-publicized deals to the database.

Regards

Steve Poile

The Top Ten

The following are the top 10 partnering deals and alliances by value, as announced in August 2011.

1. Development and commercialization agreement for Checkpoint kinase 1 (ChK-1) program - Array Biopharma, Genentech - $713m

2. Asset purchase agreement for clinical trial supplies business - Catalent Pharma Solutions, Aptuit - $410m

3. Collaborative R&D, co-manufacturing and co-commercialization agreement for ACE-536 - Celgene, Acceleron - $242m

4. Collaborative R&D agreement for Azymetric platform for development of bi-specific antibody therapeutic candidates - Merck & Co, Zymeworks - $187m

5. Collaborative R&D and licensing agreement for TGR5 agonists - Servier, Intercept Pharmaceuticals - $163m

6. Asset purchase agreement for medical business - Thoratec, Levitronix - $150m

7. Grant award for $84 million for comparative effectiveness of two initial management strategies for patients with coronary artery disease - NYU Langone Medical Center, National Heart, Lung and Blood Institute - $84m

8. Development and licensing agreement for creation of transgenic large livestock - Cellectis, Recombinetics - $50m

9. Collaborative R&D agreement for drug research - Pfizer, UCSD - $50m

10. Development and licensing agreement for VR315 combination product - GlaxoSmithKline, Vectura - $45m

Full details of each deal available at Current Agreements*
*Subscription required

Bigpharma Partnering

August saw 25 partnering deals announced where bigpharma were at least one of the parties to the deal. This is down from the 35 deals recorded in the previous month.

GlaxoSmithKline was the most active during August, signing 8 deals with partners including NPS Pharma, Vectrua, MolMed, Unigene, Enigma Diagnostics, Autifony Therapeutics, Starphama, and NCCN.

The lead deals for GlaxoSmihKline were:

  • Development and licensing agreement for VR315 combination product
  • Contract service and development agreement for production process for an investigational gene therapy for ADA-SCID (Adenosine Deaminase Deficiency - Severe Combined Immune Deficiency)

Deal Update Articles

Recent deals and alliances in life sciences - here's our take:

Array and Genentech ink $717 million Checkpoint kinase 1 cancer co-development deal
Array BioPharma and Genentech have signed a co-development pact for the development of each company's small-molecule Checkpoint kinase 1 (ChK-1) program.

 

Print Friendly, PDF & Email

Leave a Reply

 

cabannerad300x150new4gif
rauconbadgejpg
e80banner300x150animgif
cpbannerad300x150new2gif
e80banner300x150animgif
a1banner300x150animgif